New obesity drug put to the test: does it boost fat burning better than current treatment?
NCT ID NCT06745284
Summary
This study is testing whether a new obesity medication called survodutide helps the body burn fat and use energy more efficiently than an existing drug called semaglutide. Researchers will enroll 60 adults with obesity and randomly assign them to receive either survodutide or semaglutide injections once a week for 8-10 months. They'll measure how much energy participants' bodies use while sleeping in special rooms that track breathing patterns to see which medication works better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pennington Biomedical Research Center
RECRUITINGBaton Rouge, Louisiana, 70808, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Translational Research Institute for Metabolism and Diabetes
RECRUITINGOrlando, Florida, 32804, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.